U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552402) titled 'Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer' on April 13.
Brief Summary: The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Intervention:
DRUG: Oral Paclitaxel Solution Plus Fruquintinib
Patients received oral paclitaxel plus fruquintinib in 4-week cycles until disease pr...